Revolutionizing Precision Medicine with AI-Powered Platforms
Welcome to DeepTarget Biotherapeutics
Founded in June 2025, DeepTarget Bio is an innovative preclinical-stage biotechnology startup revolutionizing biomarker-driven precision medicine to address unmet medical needs. Our cutting-edge AI-powered platform propels end-to-end pipeline development with high efficiency and success rates, accelerating from groundbreaking discovery through clinical trials and into transformative therapies.
Our Unique Approach
Proprietary Agentic Bio AI System
Proprietary Agentic Bio AI System
Proprietary Agentic Bio AI System
The DeepTarget AI system, DTB.AI™, is a Large Reasoning Model (LRM), combining Inverse Reinforcement Learning and Reinforcement Learning with a human-in-the-loop framework, leveraging domain expertise feedback from our experienced drug developers.
Cutting Edge Therapeutics Design
Proprietary Agentic Bio AI System
Proprietary Agentic Bio AI System
- TSI™: Targeted -”Bio-ADC” Bi-/Tri-Specifics
- T-TCE™: Next generation T cell engager
- TSIM™: Innovative Immune Modulator
Our Vision
Empowering Drug Development Breakthroughs with DTB.AI™
- Accelerating speed, precision, efficiency, quality and scalability from discovery to clinic.
- Identifying emerging hotspots of opportunities and boosting success rates to conquer unmet needs in cancer, autoimmune diseases, and neurodegeneration.
Our Expertise
Our leadership team comprises seasoned pharmaceutical experts from Merck, Amgen, Regeneron, AstraZeneca, Teva, and Sanofi, with a proven track record in end-to-end drug development. Collectively, they have contributed to over 60 INDs, 12 BLAs, and 5 MAAs.
Our AI platform team brings over 20 years of combined experience from senior engineers at Microsoft and Amazon in AI model development, complemented by AI-driven drug discovery pioneers from biopharma—powering cutting-edge solutions with deep scientific insight.
Our Values
Value Proposition: Unlocking the Future of Precision Medicine